Chemokines and chemokine receptors in inflammatory bowel disease: Recent findings and future perspectives

Drug Discov Today. 2022 Apr;27(4):1167-1175. doi: 10.1016/j.drudis.2021.12.004. Epub 2021 Dec 9.

Abstract

Despite the benefits of current therapeutic options for treating inflammatory bowel disease (IBD), there are still patients who are refractory to these therapies. Moreover, the relapses caused by incomplete intestinal mucosa healing are frequent. Therefore, there is a need for novel pharmacological targets that can improve the existing IBD therapeutic armamentarium. Chemokine and chemokine receptors have emerged as appealing options to this end. As well as controlling leukocyte trafficking to inflamed tissues, these proteins regulate many other processes related to the development of intestinal inflammation. In this review, we summarise the most recent preclinical studies, along with the putative application of chemokine-based therapies in patients with IBD.

Keywords: Chemokines; Epithelial barrier; Intestinal inflammation; Leukocyte trafficking; Resolution of inflammation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Chemokines
  • Humans
  • Inflammatory Bowel Diseases* / drug therapy
  • Inflammatory Bowel Diseases* / etiology
  • Intestinal Mucosa / metabolism
  • Leukocytes
  • Receptors, Chemokine*

Substances

  • Chemokines
  • Receptors, Chemokine